Eli Lilly (NYSE:LLY) yesterday dosed the first patient in a trial of its automated insulin delivery system.
The system is a hybrid closed-loop platform that includes a connected insulin pump, a dosing algorithm and a continuous glucose monitor.
“This trial is a significant step forward for Lilly’s Connected Care program, moving the Connected Diabetes Ecosystem closer to hopefully becoming available to the millions of people with diabetes who need a simpler, more effective way to use insulin,” Marie Schiller, VP of the company’s connected care unit, said in prepared remarks.
The insulin-maker is developing two platforms for its Connected Diabetes Ecosystem – an automated insulin delivery system and an integrated insulin management system. The latter combines a connected insulin pen with glucose-sensing tech and software to create personalized insulin dose recommendations.
Both systems are in development and are slated to enter clinical trials for people with Type I and Type II diabetes within the coming months, Lilly reported.
Contingent upon FDA approval, Lilly expects that these technologies will reach the market in two to three years.
